criterion were more prevalent but did not distinguish between the different diagnostic certainty groups.
Dr. te Riele and colleagues highlight that at the time of data collection, only 49 of 142 patients had undergone genetic testing. Despite the undisputed value of genetic testing both within and outside of the Task Force Criteria, important limitations of genetic testing must be recognized: up to 50% of ARVC patients are gene-elusive, and 30% to 40% of genepositive patients remain nonpenetrant well into adulthood (5) . Thus, at present, the presence of an ARVC mutation cannot provide an alternate standard for the presence of ARVC disease.
Once again, we would like to thank Dr. te Riele and colleagues for their critical review of our work and for highlighting important areas for future research. In a disease that contributes significantly to pediatric and young adult sudden death, and which, once established in the adult, is likely difficult to reverse, improvements in pediatric diagnosis will be paramount. In the current study, the authors report 31 eligible patients of 122 patients undergoing TT. This means a 74.6% TT success rate at most, which is relatively low compared with current evidence (2) (3) (4) (5) .
*
This may be caused by the type of TT agents or protocols used in the current study. We have JACC VOL. 66, NO. 7, 2015 Letters A U G U S T 1 8 , 2 0 1 5 : 8 7 1 -6 previously reported that repeated doses of low-dose (25 mg) and slow infusion (6 h) alteplase under the guidance of serial TEE was superior to faster infusion and/or higher dose protocols or streptokinase (2) . This protocol provided favorable results even in pregnant patients with PVT (3). In addition, we have very recently reported that ultra-slow (25 h) infusion of low-dose (25 mg) alteplase without bolus appears to be associated with quite low complications and mortality for PVT patients without compromising post-thrombolytic success, except for those with New York Heart Association functional class IV. The TT success rate was 90% in this study (4) .
We agree with the authors that the rate of adverse events is high in PVT patients followed with oral anticoagulation after failed TT. Although the improvement of New York Heart Association functional class at least 1 step was associated with lower major complication rates, the number of patients is too small to draw a conclusion that reoperation may be delayed in these patients. We believe that reserving oral anti- Please note: The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
